Inhibition of cytokine production
    2.
    发明授权
    Inhibition of cytokine production 失效
    抑制细胞因子产生

    公开(公告)号:US5525629A

    公开(公告)日:1996-06-11

    申请号:US146083

    申请日:1993-11-04

    摘要: Hydroxamic acid derivatives of formula (I): ##STR1## wherein R.sup.1 represents hydrogen or an (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxycarbonyl(C.sub.1 -C.sub.6)alkyl, phenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl, phenacyl or substituted phenacyl group;R.sup.2 represents hydrogen or a (C.sub.1 -C.sub.6)alkyl, (C.sub.2 -C.sub.6)alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group,R.sup.3 represents a group --CH.sub.2 CO.sub.2 (C.sub.1 -C.sub.4)alkyl or --CH.sub.2 CH.sub.2 CO.sub.2 (C.sub.1 -C.sub.4)alkyl;R.sup.4 represents hydrogen or a (C.sub.1 -C.sub.6)alkyl or phenyl(C.sub.1 -C.sub.6)alkyl group;R.sup.5 represents hydrogen or a methyl group;n is 0, 1 or 2;and A represents a (C.sub.1 -C.sub.6)hydrocarbon chain optionally substituted with one or more (C.sub.1 -C.sub.6)alkyl, phenyl, or substituted phenyl groups;or a salts, solvates or hydrates thereof, are inhibitors of tumour necrosis factor production and of matrix metalloproteinases.

    摘要翻译: PCT No.PCT / GB93 / 00706 Sec。 371日期:1993年11月4日 102(e)日期1993年11月4日PCT 1993年4月5日PCT PCT。 第WO93 / 20047号公报 式(I)的羟氨基酸衍生物:(C1-C6)烷基,(C1-C6)烷氧基羰基(C1-C6)烷基,苯基,取代苯基,苯基(C1-C6)烷基, 杂环基,(C1-C6)烷基羰基,苯甲酰甲基或取代的苯甲酰甲基; R2表示氢或(C1-C6)烷基,(C2-C6)烯基,苯基(C1-C6)烷基,环烷基(C1-C6)烷基或环烯基(C1-C6)烷基,R3表示基团-CH2CO2 (C 1 -C 4)烷基或-CH 2 CH 2 CO 2(C 1 -C 4)烷基; R4表示氢或(C1-C6)烷基或苯基(C1-C6)烷基; R5代表氢或甲基; n为0,1或2; 并且A表示任选被一个或多个(C 1 -C 6)烷基,苯基或取代的苯基取代的(C 1 -C 6)烃链; 或其盐,溶剂化物或水合物,是肿瘤坏死因子产生抑制剂和基质金属蛋白酶的抑制剂。

    Hydroxamic acid based collagenase inhibitors
    5.
    发明授权
    Hydroxamic acid based collagenase inhibitors 失效
    基于羟肟酸的胶原酶抑制剂

    公开(公告)号:US5530161A

    公开(公告)日:1996-06-25

    申请号:US195818

    申请日:1994-02-14

    摘要: Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a C.sub.1 -C.sub.6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl phenacyl or substituted phenacyl group; or, when n=O, R.sup.1 represents SR.sup.x, wherein R.sup.x represents a group: ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group;R.sup.3 represents an amino acid residue with R or S stereochemistry or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6 alkoxy)benzyl or benzyloxy(C.sub.1 -C.sub.6 alkyl) group;R.sup.4 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;R.sup.5 represents a hydrogen atom or a methyl group;n is an integer having the value 0, 1 or 2; andA represents a C.sub.1 -C.sub.6 hydrocarbon chain, optionaly substituted with one or more C.sub.1 -C.sub.6 alkyl, phenyl or substituted phenyl groups;and their salts and N-oxides are collagenase inhibitors are and useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumor invasion.

    摘要翻译: 通式I的化合物:其中:R1表示C1-C6烷基,苯基,噻吩基,取代的苯基,苯基(C1-C6)烷基,杂环基,(C1-C6)烷基羰基苯甲酰甲基或取代的苯甲酰甲基 ; 或者当n = O时,R1表示SRx,其中Rx表示一个基团:R 2表示氢原子或C 1 -C 6烷基,C 1 -C 6烯基,苯基(C 1 -C 6)烷基,环烷基(C 1 -C 6 )烷基或环烯基(C 1 -C 6)烷基; R3表示具有R或S立体化学的氨基酸残基或C1-C6烷基,苄基,(C1-C6烷氧基)苄基或苄氧基(C1-C6烷基)基团; R4表示氢原子或C1-C6烷基; R5表示氢原子或甲基; n是0或1或2的整数; 且A代表C1-C6烃链,任选被一个或多个C 1 -C 6烷基,苯基或取代的苯基取代; 其盐和N-氧化物是胶原酶抑制剂,并且可用于治疗涉及组织降解和/或促进伤口愈合的疾病。 涉及组织降解的疾病包括关节病(特别是类风湿性关节炎),炎症,皮肤病,骨吸收疾病和肿瘤侵袭。

    Hydroxamic acid based collagenase inhibitors
    6.
    发明授权
    Hydroxamic acid based collagenase inhibitors 失效
    基于羟基酸的胶原蛋白抑制剂

    公开(公告)号:US5240958A

    公开(公告)日:1993-08-31

    申请号:US689848

    申请日:1991-07-08

    摘要: Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a C.sub.1 -C.sub.6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl phenacyl or substituted phenacyl group; or, when n=O, R.sup.1 represents SR.sup.x, wherein R.sup.x represents a group: ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl (C.sub.1 -C.sub.6) alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group;R.sup.3 represents an amino acid residue with R or S stereochemistry or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6 alkoxy)benzyl or benzyloxy(C.sub.1 -C.sub.6 alkyl) group;R.sup.4 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;R.sup.5 represents a hydrogen atom or a methyl group;n is an integer having the value 0, 1 or 2; andA represents a C.sub.1 -C.sub.6 hydrocarbon chain, optionaly substituted with one or more C.sub.1 -C.sub.6 alkyl, phenyl or substituted phenyl groups;and their salts and N-oxides are collagenase inhibitors are and useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumour invasion.

    摘要翻译: PCT No.PCT / GB89 / 01399 Sec。 371日期:1991年7月8日 102(e)日期1991年7月8日PCT提交1989年11月23日PCT公布。 公开号WO90 / 05719 通式I的化合物:其中:R1表示C1-C6烷基,苯基,噻吩基,取代的苯基,苯基(C1-C6)烷基,杂环基,(C1-C6)烷基, 烷基羰基苯甲酰甲基或取代苯甲酰甲基; 或者当n = O时,R1表示SRx,其中Rx表示一个基团:R 2表示氢原子或C 1 -C 6烷基,C 1 -C 6烯基,苯基(C 1 -C 6)烷基,环烷基(C 1 -C 6 )烷基或环烯基(C 1 -C 6)烷基; R 3表示具有R或S立体化学的氨基酸残基或C1-C6烷基,苄基,(C1-C6烷氧基)苄基或苄氧基(C1-C6烷基)基团; R4表示氢原子或C1-C6烷基; R5表示氢原子或甲基; n是0或1或2的整数; 且A代表C1-C6烃链,任选被一个或多个C 1 -C 6烷基,苯基或取代的苯基取代; 其盐和N-氧化物是胶原酶抑制剂,并且可用于治疗涉及组织降解和/或促进伤口愈合的疾病。 涉及组织降解的疾病包括关节病(特别是类风湿性关节炎),炎症,皮肤病,骨吸收疾病和肿瘤侵袭。

    Hydroxamino acid based collagenase inhibitors
    8.
    发明授权
    Hydroxamino acid based collagenase inhibitors 失效
    羟基氨基酸胶原酶抑制剂

    公开(公告)号:US5310763A

    公开(公告)日:1994-05-10

    申请号:US048413

    申请日:1993-04-14

    摘要: Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a C.sub.1 -C.sub.6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl phenacyl or substituted phenacyl group; or, when n=O, R.sup.1 represents SR.sup.x, wherein R.sup.x represents a group: ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group;R.sup.3 represents an amino acid residue with R or S stereochemistry or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6 alkoxy)benzyl or benzyloxy(C.sub.1 -C.sub.6 alkyl) group;R.sup.4 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;R.sup.5 represents a hydrogen atom or a methyl group;n is an integer having the value 0, 1 or 2; andA represents a C.sub.1 -C.sub.6 hydrocarbon chain, optionaly substituted with one or more C.sub.1 -C.sub.6 alkyl, phenyl or substituted phenyl groups;and their salts and N-oxides are collagenase inhibitors are and useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumor invasion.

    摘要翻译: 通式I的化合物:其中:R1表示C1-C6烷基,苯基,噻吩基,取代的苯基,苯基(C1-C6)烷基,杂环基,(C1-C6)烷基羰基苯甲酰甲基或取代的苯甲酰甲基 ; 或者当n = O时,R1表示SRx,其中Rx表示一个基团:R 2表示氢原子或C 1 -C 6烷基,C 1 -C 6烯基,苯基(C 1 -C 6)烷基,环烷基(C 1 -C 6 )烷基或环烯基(C 1 -C 6)烷基; R 3表示具有R或S立体化学的氨基酸残基或C1-C6烷基,苄基,(C1-C6烷氧基)苄基或苄氧基(C1-C6烷基)基团; R4表示氢原子或C1-C6烷基; R5表示氢原子或甲基; n是0或1或2的整数; 且A代表C1-C6烃链,任选被一个或多个C 1 -C 6烷基,苯基或取代的苯基取代; 其盐和N-氧化物是胶原酶抑制剂,并且可用于治疗涉及组织降解和/或促进伤口愈合的疾病。 涉及组织降解的疾病包括关节病(特别是类风湿性关节炎),炎症,皮肤病,骨吸收疾病和肿瘤侵袭。

    Hydroxamic acid collagenase inhibotors
    9.
    发明授权
    Hydroxamic acid collagenase inhibotors 失效
    羟肟酸胶原酶抑制剂

    公开(公告)号:US5304604A

    公开(公告)日:1994-04-19

    申请号:US674363

    申请日:1991-04-15

    摘要: Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, C.sub.1 -C.sub.6 alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl(C.sub.1 -C.sub.6)alkylthiomethyl or heterocyclylthiomethyl group; or R.sup.1 represents --SR.sup.x wherein R.sup.x represents a group ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl, or cycloalkenyl(C.sub.1 -C.sub.6)alkyl;R.sup.3 represents an amino acid residue with R or S stereochemistry or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6)alkoxybenzyl or benzyloxy(C.sub.1 -C.sub.6)alkyl group;R.sup.4 represents a hydrogen atom or a methyl group;n is an integer from 1 to 6; andA represents the group --NH.sub.2, a substituted acyclic amine or a heterocyclic base;or a salt and/or N-oxide and/or (where the compound is a thio-compound) a sulphoxide or sulphone thereof have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumour invasion.

    摘要翻译: PCT No.PCT / GB89 / 01398 Sec。 371日期:1991年4月15日 102(e)日期1991年4月15日PCT提交1989年11月23日PCT公布。 出版物WO90 / 05716 通式I的化合物:(*化学结构*)(I)其中:R1表示氢原子或C1-C6烷基,C1-C6烯基,苯基,苯基(C1-C6)烷基, C 1 -C 6烷基硫甲基,苯硫基甲基,取代的苯硫基甲基,苯基(C 1 -C 6)烷硫基甲基或杂环硫基甲基; 或R1表示-SRx,其中Rx表示基团(*化学结构*)R 2表示氢原子或C 1 -C 6烷基,C 1 -C 6烯基,苯基(C 1 -C 6)烷基,环烷基(C 1 -C 6)烷基或 环烯基(C 1 -C 6)烷基; R 3表示具有R或S立体化学的氨基酸残基或C1-C6烷基,苄基,(C1-C6)烷氧基苄基或苄氧基(C1-C6)烷基; R4代表氢原子或甲基; n是1至6的整数; 并且A表示基团-NH 2,取代的无环胺或杂环碱基; 或盐和/或N-氧化物和/或(其中化合物是硫代化合物),其亚砜或其砜具有胶原酶抑制活性,并且可用于治疗涉及组织降解和/或促进伤口愈合的疾病 。 涉及组织降解的疾病包括关节病(特别是类风湿性关节炎),炎症,皮肤病,骨吸收疾病和肿瘤侵袭。

    Antibacterial 1-normon-2-yl-heterocyclic compounds
    10.
    发明授权
    Antibacterial 1-normon-2-yl-heterocyclic compounds 失效
    抗菌1-正二-2-基 - 杂环化合物

    公开(公告)号:US4861788A

    公开(公告)日:1989-08-29

    申请号:US8893

    申请日:1987-01-30

    摘要: Compounds of formula (I): ##STR1## wherein ##STR2## is a 5-membered heterocyclic group having a 6-.pi.electron system, the five ring atoms being either(a) one carbon atom and four atoms selected from carbon and nitrogen,(b) two carbon atoms, two nitrogen atoms and one atom selected from oxygen and sulphur, or(c) four carbon atoms and one atom selected from oxygen and sulphurand R.sup.1 is a substituent on a carbon or nitrogen of ##STR3## selected from C.sub.1-20 alkyl, C.sub.2-8 alkenyl aryl, aralkyl and heterocyclyl, each of which may optionally be substituted; hydrogen and C.sub.3-7 cycloalkyl,and, where appropriate, R.sup.2 is a substituent on a carbon or nitrogen of ##STR4## and when present is the same or different to R.sup.1 and is selected from C.sub.1-20 alkyl, C.sub.2-8 alkenyl, aryl, aralkyl and heterocyclyl each of which may optionally be substituted; hydrogen and C.sub.3-7 cycloalkyl, have antibacterial and antimycoplasmal activity.

    摘要翻译: 式(I)的化合物:其中是具有6-pi电子系统的5元杂环基,5个环原子是(a)一个碳原子和选自碳的四个原子 和氮,(b)两个碳原子,两个氮原子和一个选自氧和硫的原子,或(c)四个碳原子和一个选自氧和硫的原子,并且R1是